Structure Therapeutics Inc. (GPCR) stock
GPCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$18.17−0.40 (-2.15%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Structure Therapeutics cash
Cash and short-term investments held at the end of each period.
Structure Therapeutics's cash was $1.34B at Jun 30, 2026. For fiscal 2025 it was $1.45B, up 63.7% from the year before. The highest annual figure on record is $1.45B in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.45B | +63.7% |
| FY2024 | Dec 31, 2024 | $883.50M | +89.1% |
| FY2023 | Dec 31, 2023 | $467.30M | +414.4% |
| FY2022 | Dec 31, 2022 | $90.84M | -13.7% |
| FY2021 | Dec 31, 2021 | $105.31M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.34B | +70.7% |
| Q1 FY2026 | Mar 31, 2026 | $1.46B | +74.3% |
| Q4 FY2025 | Dec 31, 2025 | $1.45B | +63.7% |
| Q3 FY2025 | Sep 30, 2025 | $799.00M | -12.7% |
| Q2 FY2025 | Jun 30, 2025 | $786.50M | -15.2% |
| Q1 FY2025 | Mar 31, 2025 | $836.90M | +91.8% |
| Q4 FY2024 | Dec 31, 2024 | $883.50M | +89.1% |
| Q3 FY2024 | Sep 30, 2024 | $915.30M | +345.6% |
| Q2 FY2024 | Jun 30, 2024 | $927.10M | +312.8% |
| Q1 FY2024 | Mar 31, 2024 | $436.40M | +81.2% |
| Q4 FY2023 | Dec 31, 2023 | $467.30M | +414.4% |
| Q3 FY2023 | Sep 30, 2023 | $205.40M | +631.2% |
| Q2 FY2023 | Jun 30, 2023 | $224.60M | +304.8% |
| Q1 FY2023 | Mar 31, 2023 | $240.90M | +375.9% |
| Q4 FY2022 | Dec 31, 2022 | $90.84M | -13.7% |
| Q3 FY2022 | Sep 30, 2022 | $28.09M | – |
| Q2 FY2022 | Jun 30, 2022 | $55.49M | – |
| Q1 FY2022 | Mar 31, 2022 | $50.62M | – |
| Q4 FY2021 | Dec 31, 2021 | $105.31M | – |
See a number that looks wrong?